Jump Financial’s DiaMedica Therapeutics DMAC Stock Holding History

Jump Financial’s Portfolio DMAC Stock Details DMAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-11,243	Closed	-$89.5K	–	2003
2025 Q4	$89.5K	Buy	+11,243	New	+$84.1K	﹤0.01%	1836
2022 Q1	–	Sell	-21,800	Closed	-$81K	–	1626
2021 Q4	$81K	Buy	21,800 +3,500	+19%	+$13.7K	0.01%	1253
2021 Q3	$73K	Buy	+18,300	New	+$70K	0.01%	1007

Other funds holding DMAC

CLG

Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PAPAIJV

Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Jump Financial's DMAC Position: Q1 2026 in Review

Jump Financial sold out of DiaMedica Therapeutics (DMAC) in Q1 2026, closing a stake of 11,243 shares — an estimated $89.5K sold.

Jump Financial first reported a position in DMAC in Q3 2021 and held it in 3 quarters. The position peaked at $89.5K in Q4 2025. 98 funds tracked by Wall St. Rank hold DMAC as of Q1 2026.

Jump Financial reported no remaining DiaMedica Therapeutics position as of Q1 2026 after selling out during the quarter.
Jump Financial sold 11,243 DiaMedica Therapeutics shares in Q1 2026, an estimated $89.5K.
Jump Financial first reported a position in DiaMedica Therapeutics in Q3 2021 and held it in 3 quarters.
Jump Financial's DiaMedica Therapeutics position peaked at $89.5K in Q4 2025.
98 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q1 2026.

Based on Jump Financial's 13F filing for Q1 2026, filed 14 May 2026.